A supplier audit is most useful when its scope matches the work being purchased. A general tour, questionnaire or certificate may leave the critical manufacturing, testing or recordkeeping activity unexamined. Define the question before deciding whether an audit answers it.

FDA's contract-manufacturing guidance recommends documented quality responsibilities between parties. Although it addresses regulated drug manufacturing, its allocation-of-responsibility principle helps explain why outsourcing does not eliminate the need to understand who controls each activity. FDA contract manufacturing quality agreements

Map the responsibilities

Identify who manufactures, repackages, tests, releases and ships the material. Then identify which of those activities the audit actually covered. An audit of a distributor's order-processing system may tell little about the original manufacturer's controls.

A report should also be evaluated for timing and follow-through. A finding is not resolved merely because a corrective action was promised. The evidence should show what changed and how the correction was assessed. Conversely, the presence of a finding does not by itself justify a sweeping conclusion that every product is defective.

Use proportionate review

Not every exploratory research purchase requires the same depth of investigation. The institution should decide the appropriate level based on the material, intended experiment and consequence of an error. The review should remain focused on those risks rather than collecting documents for their own sake.

For AXON readers, an audit claim is best summarized as a dated assessment of a specified organization and scope. It is not a permanent guarantee of quality, a substitute for lot-specific evidence or proof of clinical safety. This article offers no audit findings about a named supplier and should not be used as a certification statement.